Beyond Pushing Buttons: Sitting Down With Emanuela Gionfriddo
-
By
-
James Strachan
-
November 18, 2026
-
15 min
By
James Strachan
November 18, 2026
Median progression-free survival was 10 vs 5.5 months with giredestrant vs comparator therapy.
by Mouj Hijazi
November 17, 2026
November 17, 2026
Approved for metastatic and early-stage breast cancer, the biosimilar cannot launch in the US before Q3 2028.
by Mouj Hijazi
November 17, 2026